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Objective: Cancer patients receiving chemotherapy are at increased risk of anemia. 
We   conducted a population-based historical cohort study in newly diagnosed cancer patients with 
  chemotherapy-associated anemia in order to characterize red blood cell transfusion (RBCT) use.
Design: This study evaluated cancer patients diagnosed between January 1, 1998 and December 
31, 2003 using Danish National Patient Registry data. Patients were receiving chemotherapy 
and had a hemoglobin level #10.9 g/dL during the 4 months following cancer diagnosis. 
We   characterized patterns of RBCT use and inpatient and outpatient hospitalization for 
  transfusion. Adjusted Poisson regression models were used to evaluate the likelihood of RBCT, 
estimated by relative risk (RR), based on demographic and clinical factors.
Results: Women constituted 58% of 1782 patients studied; the median age was 58 years. 
Two-thirds (67%) had solid tumors; 67% had stage III or IV disease at diagnosis. Overall, 713 
(40%) patients received an RBCT within 120 days of cancer diagnosis, of which 94% were 
administered in the inpatient setting; 84% of these patients required subsequent transfusions. 
The median (Q1, Q3) pretransfusion hemoglobin level was 9.0 (8.4, 9.8) g/dL. Patients 
aged ,20 years were more likely to receive an RBCT than older patients (RR 1.89; 95% 
confidence interval [CI] 1.44–2.49). Compared with stage IV disease, those with stage II or III 
disease had a lower likelihood of RBCT (stage II: RR 0.52, 95% CI: 0.37–0.72; stage III: 
RR 0.68, 95% CI: 0.55–0.83). Patients diagnosed with breast cancer were less likely to receive 
an RBCT than patients with hematologic cancers (RR 0.34, 95% CI: 0.21–0.55).
Conclusion: In this study, 40% of cancer patients with chemotherapy-associated anemia in 
Western Denmark received an RBCT, usually in the inpatient setting; of these, most required 
subsequent transfusions. Younger age increased the likelihood of receiving an RBCT, and earlier 
stage or breast cancer decreased RBCT likelihood.
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Introduction
Patients with cancer can develop anemia, which is associated with decreased   functional 
capacity and quality of life and shorter survival; anemia in cancer develops most often in 
response to chemotherapy.1,2 In the European Cancer Anemia Survey (ECAS),   anemia 
(defined as a hemoglobin level ,12 g/dL) was reported in 62.7% of patients who 
received their first chemotherapy treatment during the study and who were not anemic 
at enrollment.3 Rates were higher for patients with some tumor types, including lung 
cancer (77%) and gynecologic cancers (81%). Among patients who were anemic at least Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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once during the ECAS, those receiving chemotherapy were 
more likely to experience anemia than were untreated patients 
(75% vs 40%).3
Until the 1990s, red blood cell transfusion (RBCT) was the 
only option for treating chemotherapy-associated anemia.4,5 
Emerging concerns about the availability of   sufficient 
  quantities of safe blood products and transfusion-related risks 
led to the increasing use of erythropoiesis-stimulating agents 
(ESAs) in place of RBCTs.6–8 Recently, however, guidelines 
for the use of ESAs have been changed,9–13 stimulating 
renewed interest in RBCTs.
The use of blood products in Denmark has previously 
been reported to be the highest in Europe because of 
the extensive availability of donated blood and easier 
access to inexpensive blood products.14 Blood donation is 
  considered a civic responsibility in Denmark, and voluntary 
  nonremunerated blood donations provide for the highest level 
of transfusions per capita in the world. In this setting, the 
current study was undertaken to characterize the use of RBCT 
among newly diagnosed cancer patients receiving chemo-
therapy. This study examined the proportion of patients with 
chemotherapy-associated anemia who received their first and 
subsequent RBCTs, the hemoglobin levels before and after 
the first RBCT, the use of health care resource utilization 
related to RBCT, and the predictors for RBCT.
Materials and methods
study design and population
This was a population-based historical cohort study. Residents 
of the counties of Aarhus and North Jutland in Western 
  Denmark constituted the source population for the study 
(approximately 1.2 million people). The Danish National 
Health Service provides tax-supported free health care for the 
entire Danish population, and each citizen of Denmark has a 
unique civil personal registration (CPR) number. The CPR 
number is used to link various health care   databases under 
the auspices of the Danish Government. The   Danish National 
Registry of Patients (DNRP) collects data from all patients 
admitted to hospitals, emergency rooms, and outpatient   clinics. 
Admissions to hospitals have been registered since 1977, and 
contacts to emergency units and outpatient   clinics have been 
registered since 1995. More than 99% of all discharges from 
Danish nonpsychiatric hospital   departments are recorded in 
the DNRP.15 The Danish Cancer   Registry (DCR), which has 
recorded incident cases of cancer throughout the country since 
1943, provides accurate and almost complete   identification 
of cancer cases.16   Reporting of new cases of cancer has been 
required by Danish law since 1987.16 The Danish   Transfusion 
Data Base (DTDB) records all patients receiving blood 
transfusions and describes the use of blood components in 
Denmark, including the number of blood components trans-
fused and the concentration of hemoglobin at each visit. The 
DTDB obtains the transfusion data directly from the blood 
bank systems in which registration of all blood products is 
mandatory according to Danish law. The number of transfu-
sions registered in the DTDB is in accordance with the official 
statistics on use of blood products in Denmark reported by 
the Danish Medicines Agency.17
In this study, the DCR was searched to identify eligible 
patients newly diagnosed with cancer by type between 
January 1, 1998 and December 31, 2003 (Table 1). The DCR 
was then linked to the DTDB to identify chemotherapy-
treated patients with anemia, defined as a hemoglobin level 
#10.9 g/dL. To be eligible for the study, patients had to have 
received chemotherapy within the first 4 months after their 
cancer diagnosis. Patients with renal disease, pre-existing 
anemia, or those receiving radiation therapy either alone or 
in combination with another therapy were excluded.
We examined patient demographic and clinical charac-
teristics including tumor site, tumor stage at diagnosis, age at 
diagnosis, and hemoglobin level before and after transfusion. 
We evaluated the proportion of patients with chemotherapy-
associated anemia receiving an RBCT and subsequent RBCT 
by tumor type, by solid tumors versus hematologic cancers, 
and by cancer stage. We also assessed the number of RBC 
units administered in the first and subsequent transfusions. 
Using the DTDB and the DNRP, transfusions were linked to 
hospital visits. We assessed health care resource utilization 
related to RBCT (ie, inpatient hospitalizations, outpatient 
physician visits, and emergency room visits).
statistical analyses
Descriptive statistics, including medians with first and third 
quartiles (Q1, Q3) or minimum and maximum values, were 
calculated for continuous variables. Counts and proportions 
were calculated for categorical variables.
Because of the high prevalence of RBCTs observed in 
our study, which may lead to convergence problems, Poisson 
regression rather than logistic regression was used to estimate 
the relative risk (RR) of RBCT with 95% confidence intervals 
(CI),18,19 adjusting for cancer type (hematologic cancers or 
solid tumors) or cancer site (hematologic; colorectal and 
gastrointestinal; gynecologic, urinary tract, and prostate; 
lung; breast; and other, which included endocrinal glands, 
bone, melanoma of skin, connective tissue, and unspecified 
male genital organs, testis, eye, brain and nervous system, Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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thyroid, metastases, nonmelanoma of skin, peritoneum, and 
unspecified connective tissue). All analyses were   carried out 
using the statistical software SAS®, Version 9.2 (SAS   Institute 
Inc., Cary, NC, USA).
Results
We identified 28,272 incident cancer patients in the DCR. 
Of these, 3878 received chemotherapy within the 4 months 
after diagnosis; 298 were excluded because they were 
  diagnosed with renal disease or pre-existing anemia or were 
receiving radiation therapy either alone or in combination 
with another therapy. Of the 3580 patients remaining, 1782 
had anemia (hemoglobin #10.9 g/dL).
Demographics and clinical characteristics 
of patients with chemotherapy-associated 
anemia
The majority of patients with chemotherapy-associated 
anemia in the study (N = 1782) were female (58%) with 
a median age (minimum, maximum) of 58 (0.1, 90) years 
(Table 2). Ninety-eight patients (5.5%) were less than 20 years 
of age. Approximately two-thirds of patients had solid tumors, 
with the remainder diagnosed with hematologic cancers. 
The majority of patients were diagnosed with stage III or IV 
  disease, with differences by tumor type shown in Table 2.
red blood cell transfusions in patients 
with chemotherapy-associated anemia
Overall, a total of 713 of 1782 (40%) patients received 
an RBCT within 120 days of cancer diagnosis (Figure 1). 
Among these patients, approximately 23% underwent 
  surgery,   including 159 patients (22%) with solid tumors 
and eight patients (1%) with hematologic malignancies 
(data not shown). RBCTs were administered most frequently 
to patients with hematologic cancers (47%) and lung   cancer 
(20%) (Figure 1). In contrast, only 2% of breast cancer 
patients and 3% of gastrointestinal cancer patients received 
an RBCT. Among patients whose cancer stage was known, 
RBCTs were administered most frequently to patients with 
stage IV disease (42%).
Similar patterns were observed for subsequent RBCTs 
within 90 days after the first transfusion (Figure 1). Among 
those who had a first transfusion, 84% (600 of 713) received a 
subsequent transfusion; most were patients with hematologic 
cancers (51%) or lung cancer (20%). Only 3% of breast 
cancer patients required subsequent transfusions. As was 
oberved in patients receiving a first transfusion, the   highest 
proportion of those receiving subsequent RBCTs were 
patients with stage IV disease (42%, Figure 2).
Overall, patients received a median (Q1, Q3) of 2 (1, 2) 
RBC units in their first transfusion, a pattern that was   similar 
among patients with all tumor types (data not shown). 
A median (Q1, Q3) of 5 (3, 10) RBC units were administered 
to patients who received a subsequent transfusion. Patients 
with hematologic cancers or with stage II disease required 
more RBC units in subsequent transfusions; the median 
Table  1  Cancer  codes  in  the  International  Classification  of 
Diseases, 7th revision (iCD-7)24
Malignancy type ICD-7 codesa
hematologic non-hodgkin’s lymphoma 64, 68
hodgkin’s lymphoma 65
Multiple myeloma 66
Leukemia 67
gastrointestinal Esophagus 19
stomach 20
small intestine 21
Liver 24, 26
gallbladder 25
Pancreas 27
Urinary tract Kidney 48
Urinary bladder 49
Prostate Prostate 44
Lung Lung 32, 33, 34
Mediastinum 35
gynecologic Cervix uteri 38
Corpus uteri 39, 40
Ovary 41
Other and unspecified  
female genital organs
42
head and neck Lip 13
Tongue 14
salivary glands 15
Mouth 16
Pharynx 17
nasal cavities and sinuses 30
Larynx 31
Breast Breast 36
Colorectal Colon 22
rectum 23
Other Other and unspecified sites 62
Endocrinal glands 57
Bone 58
Melanoma of skin 51
Connective tissue 59
Other and unspecified  
male genital organs
46
Testis 45
Eye 54
Brain and nervous system 55
Thyroid 56
Metastases 61
nonmelanoma of skin 52
Peritoneum and unspecified  
connective tissue
28
Note: aOnly the first two digits of the ICD-7 codes are listed.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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(Q1, Q3) was 8 (4, 17) RBC units for hematologic cancers 
and 7 (2, 8) RBC units for stage II disease.
Among patients with chemotherapy-associated anemia 
who received a transfusion, the median (Q1, Q3)   hemoglobin 
level before the first transfusion was 9.0 g/dL (8.4, 9.8); 5% of 
patients had hemoglobin levels of 6.8 g/dL or lower (  Figure 3). 
The median (Q1, Q3) hemoglobin value reached 10.8 g/dL 
(9.7, 11.8) within 5 days after   transfusion. The median 
(Q1, Q3) time from the first hemoglobin   measurement to 
  transfusion was 1 (1.0, 3.0) day.
Predictors of red blood cell  
transfusion in chemotherapy-associated 
anemia patients
Age, tumor stage, and tumor site were significant predictors of 
RBCT after adjusting for cancer type or tumor site (Table 3). 
An approximately two-fold increase in the likelihood of 
RBCT was found for chemotherapy-associated anemia 
patients younger than 20 years (RR 2.08, 95% CI: 1.58–2.73 
adjusted for tumor type; RR 1.89, 95% CI: 1.44–2.49 adjusted 
for tumor site). Stage II or stage III disease was a predictor 
of decreased likelihood of RBCT compared with stage IV 
disease (stage II, RR 0.47, 95% CI: 0.34–0.65 adjusted for 
tumor type; RR 0.52, 95% CI: 0.37–0.72 adjusted for tumor 
site; stage III, RR 0.66, 95% CI: 0.54–0.81 adjusted for 
tumor type; RR 0.68, 95% CI: 0.55–0.83 adjusted for tumor 
site). The likelihood of transfusion was reduced for patients 
with breast cancer compared with those with hematologic 
cancers (RR 0.34, 95% CI: 0.21–0.55) (Table 3).
health care resource utilization in patients 
with chemotherapy-associated anemia
Of the 713 patients with chemotherapy-associated anemia 
who received an RBCT within 120 days of cancer diagnosis, 
667 transfusions (94%) were administered in the inpatient 
  setting, 36 (5%) in the outpatient setting, and none in the 
emergency room setting; we could not link 10   transfusions 
(1%) to a specific hospital visit. The diagnoses of the 
667 patients who received transfusions in the inpatient   setting 
were approximately equally divided between   hematologic 
cancers (48.6%) and solid tumors (51.4%) (Table 4). 
  Inpatient transfusion recipients included 276 patients (41%) 
with stage IV disease and 133 patients (20%) with stage III 
disease. Stage at diagnosis was unspecified for 215 patients 
(32%) who received inpatient transfusions.
The 36 outpatient transfusion recipients included 
26 patients (72%) with solid tumors and 10 (28%) with 
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  hematologic malignancies. Sixteen (44%) of these patients 
had stage IV disease and 11 (31%) had stage III disease.
Hematologic cancers were the most frequent   diagnosis 
among patients who received transfusions in both the 
  inpatient (49%) and outpatient (28%) settings (Table 4). 
Among solid tumor patients, lung cancer was the most 
frequent diagnosis for patients who received transfusions 
as inpatients (19%) or outpatients (36%) (Table 4). In the 
  inpatient setting, gynecologic cancer (9%) and   colorectal 
cancer (7%) were the next most frequent diagnoses. 
For patients who received transfusions in the outpatient 
setting, colorectal cancer (22%) and gastrointestinal cancer 
aOther includes endocrinal glands, bone, melanoma of skin, connective tissue, unspecified male
genital organs, testis, eye, brain and nervous system, thyroid, metastases, nonmelanoma of skin,
peritoneum and unspecified connective tissue   
Tumor type First transfusion
Number of
patients
Percent of
patients
Number of
patients
Percent of
patients
N = 713 N = 600
Hematologict umors 336 47.1 308 51.3
Solid tumors 377 52.9 292 48.7
Lung 143 20.1 119 19.8
Gynecologic6 18 .6 42 7.0
Colorectal6 08 .4 42 7.0
Othera 42 5.93 9 6.5
Urinary tract3 14 .3 23 3.8
Breast2 23 .1 16 2.7
Gastrointestinal 17 2.41 0 1.7
Prostate 10 .1 1 0.2
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after first transfusion
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Figure 1 Proportion of patients receiving red blood cell transfusions by tumor type: Aarhus and north Jutland, Denmark (1998–2003). Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Figure 2 Proportion of patients receiving red blood cell transfusions by cancer stage: Aarhus and north Jutland, Denmark (1998–2003).
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Q3 (75th percentile)
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Blue shaded area represents 
time before the first transfusion. 
Number of patients 251 364 422 507 577 620 625 636 646 1,281
Figure 3 Pre- and post-distribution of hemoglobin levels for the first red blood cell transfusion: Aarhus and North Jutland, Denmark (1998–2003), n = 501.
and other cancer sites (6% each) followed lung cancer in 
frequency of diagnosis (Table 4).
The median number (Q1, Q3) of transfusion-related 
inpatient visits was 2 (0, 6) for the study population overall, 
5 (0, 12) for patients with hematologic cancers, and 1 (0, 4) 
for patients with solid tumors. The median number (Q1, Q3) 
of outpatient visits within 90 days after transfusion in our 
study population was 0 (0, 0) overall (data not shown).
Discussion
In this study of patients with chemotherapy-associated anemia 
in Western Denmark, 40% of the patient   population received 
at least one RBCT, with a median total of two RBC units 
within 4 months after their cancer diagnosis. This finding is 
consistent with ECAS data, which showed that 39% of anemic 
patients received anemia treatment (RBCT, ESAs, or iron) 
at any time during the survey period.3 Among patients with Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
97
red blood cell transfusions in Western Denmark
Table 3 Likelihood of red blood cell transfusion in chemotherapy-associated anemia patients: Aarhus and north Jutland, Denmark 
(1998–2003)
Crude likelihood (RR)  
for transfusion
Likelihood (RR) for transfusion  
adjusted for tumor typea
Likelihood (RR) for transfusion   
adjusted for tumor siteb
RR (95% CI) RR (95% CI) RR (95% CI)
Gender
Female 1.00 (reference) 1.00 (reference) 1.00 (reference)
Male 1.21 (1.04–1.40) 0.94 (0.81–1.09) 0.90 (0.77–1.05)
Age (years)
0–19 2.61 (2.00–3.40) 2.08 (1.58–2.73) 1.89 (1.44–2.49)
20–49 1.00 (reference ) 1.00 (reference ) 1.00 (reference )
50–59 1.02 (0.81–1.27) 0.99 (0.79–1.25) 0.98 (0.78–1.23)
60–69 1.11 (0.89–1.38) 1.04 (0.83–1.30) 1.01 (0.81–1.27)
70–79 1.21 (0.95–1.54) 1.06 (0.83–1.35) 1.02 (0.80–1.31)
80+ 1.23 (0.81–1.85) 0.91 (0.60–1.38) 0.87 (0.57–1.31)
Tumor spread
stage i 0.42 (0.16–1.12) 0.64 (0.23–1.74) 0.48 (0.17–1.33)
stage ii 0.42 (0.30–0.57) 0.47 (0.34–0.65) 0.52 (0.37–0.72)
stage iii 0.55 (0.45–0.67) 0.66 (0.54–0.81) 0.68 (0.55–0.83)
stage iV 1.00 (reference) 1.00 (reference) 1.00 (reference)
Unspecified 1.27 (1.07–1.51) 0.93 (0.76–1.15) 0.97 (0.78–1.19)
Cancer type
hematologic cancers 1.00 (reference) 1.00 (reference)
solid tumors 0.56 (0.48–0.64) 0.87 (0.71–1.07)
Cancer site
hematologic cancers 1.00 (reference) 1.00 (reference)
Colorectal and gastrointestinal 0.45 (0.35–0.58) 0.72 (0.52–1.00)
gynecologic, urinary tract, and prostate 0.63 (0.50–0.79) 1.01 (0.74–1.37)
Lung 0.78 (0.64–0.94) 0.93 (0.73–1.17)
Breast 0.18 (0.12–0.28) 0.34 (0.21–0.55)
Other 0.78 (0.56–1.07) 1.04 (0.73–1.50)
Notes: aAdjusting for tumor type in two groups: hematologic cancers and solid tumors; bAdjusting for tumor site: hematologic cancers; colorectal and gastrointestinal; 
gynecologic, urinary tract, and prostate; lung; breast; and other, which included endocrinal glands, bone, melanoma of skin, connective tissue and unspecified male genital 
organs, testis, eye, brain and nervous system, thyroid, metastases, nonmelanoma of skin, and peritoneum and unspecified connective tissue.
Abbreviations: CI, confidence interval; RR, relative risk.
chemotherapy-associated anemia who received a   transfusion, 
a large proportion received a subsequent transfusion, with a 
median total of five RBC units within 90 days after the first 
transfusion. Although we did not have information on the 
chemotherapy cycle in which   transfusions were administered, 
this need for additional transfusion is   consistent with the study 
by Groopman and Itri,1 which reported that mean hemoglobin 
concentration decreased   progressively with treatment cycle 
for cancer patients.   Predictors of RBCT include age, cancer 
stage, and tumor site.
Among patients with chemotherapy-associated anemia 
who received a transfusion, the median hemoglobin level 
before the transfusion was 9.0 g/dL. This finding is similar 
to that of the ECAS study, in which the mean   hemoglobin 
level for initiation of anemia treatment was 9.7 g/dL.3 This 
practice is consistent with the 2008 guidelines of the   European 
Organization for Research and Treatment of   Cancer (EORTC), 
which recommend treatment of symptomatic anemia at 
a hemoglobin level from 9 g/dL to 11 g/dL and evaluation for 
transfusion if the hemoglobin level is less than 9 g/dL.10
Most transfusions in our study were administered in 
the inpatient setting, regardless of tumor type or cancer 
stage. We did not have information regarding the primary 
reason for hospital admission of these patients. However, 
patients in this study had a primary diagnosis of cancer and 
may have had multiple comorbid conditions in addition to 
chemotherapy-associated anemia; any of these might have 
led to   hospitalization. We speculate that the large   proportion 
of patients who received transfusions in the inpatient setting 
may in fact have been hospitalized for other conditions. 
Further study of these factors is warranted to develop a 
comprehensive overview of health care resource utilization 
in cancer patients with chemotherapy-associated anemia.
Our study confirms previous research on predictors of trans-
fusion use in chemotherapy-associated anemia. In our study, 
age was a predictor of RBCT in chemotherapy-associated Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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anemia patients. This result is consistent with findings from 
a large European survey of 18 major pediatric oncology 
centers in seven countries that quantified the incidence of 
anemia or treatment in the pediatric patient population. That 
survey showed that anemia is a very common complication 
in children with cancer; approximately 80% of all patients 
met the World Health Organization and EORTC criteria for 
anemia, and most patients were treated with RBCT.20 In our 
study, there was a two-fold increased likelihood for RBCT 
in patients aged younger than 20 years.
In published reports, the highest incidence of RBCTs are 
said to occur in anemic patients with lymphomas, lung tumors, 
and gynecologic (ovarian) or genitourinary tumors.3,21–23 
  Furthermore, the ECAS showed that anemic patients with 
breast cancer were least likely to receive anemia treatment. 
With the exception of gynecologic tumors, these findings 
are consistent with our results, even though the definitions 
of anemia differed among the studies. The observation of 
low transfusion rates for breast cancer could be related to the 
fact that 70% of patients with breast cancer had stage II or III 
disease (Table 2), a   predictor of decreased likelihood of RBCT 
(Table 3), whereas only 17% of patients with   hematologic 
  cancers had stage II or III disease (Table 2). The low 
  proportions of transfused patients with   chemotherapy- 
associated anemia diagnosed with hematologic and lung 
cancers who underwent surgery in our study (2% and 6%, 
respectively) suggest that RBCTs in these patients were not 
administered as a consequence of a surgical procedure.
Several study limitations should be noted. Because of 
the historical cohort design of our study, the specific reasons 
for the underlying anemia of the patients in this study are 
unknown. Also unknown is the date on which chemotherapy 
was initiated, which may have affected the timing of the 
requirement for RBCTs. Anemia could be a direct effect of 
the malignancy on the bone marrow, a result of high tumor 
burden or of biologic effects mediated by inflammatory 
  cytokines, the result of treatment, or a combination of these 
effects. Patterns of transfusion usage in Denmark differ from 
those in other countries because of the ready availability of 
donated blood, which may limit the generalizability of these 
results. In addition, populations that are racially or ethnically 
more heterogeneous may exhibit different   patterns than were 
observed in the predominantly Caucasian Danish population. 
We were not able to assess other anemia   treatments. Although 
ESAs were available throughout the study period, their use 
was not common in Western Denmark during the time period 
of this study. Examination of ESA use in the study population 
is beyond the scope of this analysis.
Strengths of this study include the population-based 
  lifelong follow-up of patients in Denmark providing 
  longitudinal capture of medical information. The CPR   number 
system allowed unambiguous individual level record linkage 
between the different registries, which have been shown to 
be accurate and virtually complete. Detailed   medical data 
were available, including information on all transfusions 
and hemoglobin values before and after   transfusions. 
This descriptive study adds to the body of   evidence about 
chemotherapy-associated anemia patients and patterns of 
RBCT in Denmark, a country with an extensively available 
blood supply, and provides a context for these   measures in 
countries with different transfusion practices.
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Table  4  healthcare  resource  utilization  for  patients  with 
chemotherapy-associated  anemia  receiving  a  red  blood  cell 
transfusion: Aarhus and north Jutland, Denmark (1998–2003)
Inpatient visit 
(n = 667)
Outpatient 
visit (n = 36)
Othera 
(n = 10)
n % n % n %
Tumor type
hematologic cancers 324 48.6 10 27.8 2 20.0
solid tumors 343 51.4 26 72.2 8 80.0
Tumor site
gastrointestinal 15 2.2 2 5.6 0 0
Urinary tract 30 4.5 0 0 1 10.0
Prostate 1 0.1 0 0 0 0
Lung 127 19.0 13 36.1 3 30.0
gynecologic 59 8.8 0 0 2 20.0
Breast 20 3.0 1 2.8 1 10.0
Colorectal 51 7.6 8 22.2 1 10.0
Otherb 40 6.0 2 5.6 0 0
Stage at diagnosis
i 4 0.6 0 0 0 0
ii 39 5.8 3 8.3 1 10.0
iii 133 19.9 11 30.6 3 30.0
iV 276 41.4 16 44.4 4 40.0
Unspecified 215 32.2 6 16.7 2 20.0
Notes: aTransfusions that could not be linked to a specific hospital visit; bincludes 
endocrinal glands, bone, melanoma of skin, connective tissue, unspecified male genital 
organs, testis, eye, brain and nervous system, thyroid, metastases, nonmelanoma of 
skin, peritoneum, and unspecified connective tissue.Clinical Epidemiology
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